If Trump wants to lower drug prices, his obvious free-riding targets are outside the US

President Donald Trump just secured nine new pricing agreements with drug manufacturers that could help reduce what Americans pay for many prescription medicines.

The deals demonstrate Trump's commitment to lowering drug prices for patients. The president's dedication – and his desire to negotiate with companies individually, rather than imposing broad mandates – is commendable. But his efforts would be better directed at the root cause of high drug prices: foreign countries free-riding on American drug innovation.